AmCAD-UT® Detection uses statistical pattern recognition and quantification methods to perform analytical processing of images. The physician may process the image for detection of sonographic characteristics (i.e., hyperechoic foci, echogenicity, texture, margin, anechoic areas, taller than wide, tumor shape, and tumor size) with assistance of AmCAD-UT® Detection. AmCAD-UT® Detection provides more detailed information with quantification and visualization of the sonographic characteristics on thyroid nodule that may assist medical professionals in making their diagnostic decision.
AmCAD-US 1.0 is a software device intended to view and quantify ultrasound image data of backscattered signals acquired from an FDA-cleared ultrasound system. The information may be useful in assisting the user’s interpretation of the variation in tissue characteristics.
AmCAD-UV 1.0 is a software device designed for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals. The generated pulsatile signals may be useful in assisting user’s interpretation of variation in hemodynamic properties of blood vessels.
Product category: Echocardiographs and evaluation systems
AmCAD-UT® Diagnosis uses statistical pattern recognition and quantification methods to perform analytical processing of images. The physicians may analyze the images of thyroid nodules based on the quantification of sonographic characteristics (i.e., hyperechoic foci, echo-pattern, echo-texture, margin,anechoic areas, tumor shape, and tumor size) by AmCAD-UT® Diagnosis. AmCAD-UT® Diagnosis not only provides more detailed information with quantification and visualization of the sonographic characteristics of thyroid nodules, but more importantly, also analyzes the malignant potential for each ultrasound feature. This product can assist medical professionals in making provisional diagnosis; avoid overtreatment, such as the unnecessary fine needle aspiration (FNA) procedure, and the patient fear caused; and also increase the prevalence of thyroid nodule examination.
AmCad BioMed Corporation (AmCad) was first founded in 2008. In 2013, AmCad was listed on Taiwan’s Emerging Stock Market and was listed on Taipex on March 24th, 2015.. AmCad’s parent companies include Maywufa Company, Ltd (Taiwan Stock Exchange, Code: 1731) and PhytoHealth Corporation (Taiwan Stock Exchange, Code: 4108). AmCad is currently developing first-in-class Computer-Aided Detection and Diagnosis (CADe/CADx) software device, based on the technology initially developed by National Taiwan University (NTU) and NTU Hospital. AmCad is a world leader in the development of CAD device for ultrasound images of thyroid nodules. AmCAD-UT® Detection has obtained US FDA 510(k) Clearance in October 2013, CE Mark approval in April 2014 and TFDA approval in January 2015. AmCad has a strong patent protected covering AmCAD-UT® products in the U.S., Europe, and Asia.